Aswin Nair
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Aswin Nair has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Debashish Danda
Department of Clinical Immunology and Rheumatology Christian Medical College Vellore India
6 shared publications - Bijesh Yadav
King Abdullah International Medical Research Centre, Riyadh 11481, Saudi Arabia
3 shared publications - George Joseph
Department of Cardiology, Christian Medical College, Vellore, India
3 shared publications - John Antony Jude Prakash
Department of Clinical Microbiology, Christian Medical College, Vellore, India
2 shared publications - Ruchika Goel
Department of Clinical Immunology and Rheumatology, Christian Medical College and Hospital (CMCH), Vellore, India
2 shared publications - Ruchika Goel
Department of Clinical Immunology and Rheumatology, Christian Medical College, Vellore, India
2 shared publications
Latest Publications
- 6 October 2023
- Published by Springer Nature in Clinical Rheumatology
- Vol. 42 (12) , 3289-3297
Clinical profile of anti-NXP-2 antibody-positive inflammatory myositis and outcome in an Indian population
Introduction Myositis-specific antibodies (MSA) play an important role in the clinical presentation and prognosis of patients with idiopathic inflammatory myositis (IIM). Anti-NXP-2 is one of the newly described MSA. Objective We aimed to describe various clinical presentations associated with anti-NXP2 antibodies and assess response to treatment. Methods In this retrospective study, the electronic medical records of all patients who tested positive for anti-NXP2 during June 2019 to April 2022 were screened. Details of demography, clinical presentation, and treatment data were recorded. The anti-NXP2 was tested using the Euro line test kit. Any patient who had an intensity of ≥1+ was considered testing positive. The diagnosis of IIM was reviewed after applying the 2017 European League of Rheumatology (EULAR)/American College of Rheumatology (ACR) criteria of myositis. Results Among the 660 suspected patients, 470 (71.2%) patients were positive for IIM, and 28 (5.95%) patients were positive for anti-NXP2. From anti-NXP2-antibody positive, 21/470 (4.46%) patients fulfilled criteria for IIM. Among 12 adult (57.14%) patients with IIM, 7 (58.33%) presented as polymyositis (PM) and 5 (41.6%) as dermatomyositis (DM) with median age at presentation of 45 (IQR: 25–58) years. Calcinosis and subcutaneous oedema were observed in 4 (19%) and 2 (9.52%), respectively; myalgia in 6 (28.6%); and distal muscle weakness in 5 (23.8%) patients. Malignancy at the time of diagnosis was observed in two adults with IIM (16.7%), one with DM (intraductal breast cancer), and another with PM (anaplastic large cell lymphoma). Remaining, 9 had juvenile dermatomyositis (JDM) with a median age of 4 (IQR: 3–8) years. Seven (77.8%) patients with JDM had skin rash specific for DM (heliotrope rash and Gottron’s papule). None of the patients had cardiac and lung involvement, while GI symptoms, especially dysphagia, were present in 5 (23.8%) patients. During a median follow-up of 19 months (IQR: 12–26 months), 19/19 patients reported improvement and were in remission with treatment. Conclusion The current study shows that adult DM patients with anti-NXP-2 autoantibodies have a unique clinical phenotype. Its presentation differs between adult and JDM, even in different parts of the world. Muscle weakness is mild and responds to treatment. Dysphagia needs more time and aggressive IS for improvement as compared to other muscle involvement. Key Points • Anti-NXP-2 antibody presentation varied from adult to child, as in different parts of the world. • In Indian adult patients, non-specific skin manifestations were more common, whereas in JDM, specific skin features were common. • There was less likely involvement of the lung and heart. But more risk of GI involvement requiring aggressive management. • Adult with anti-NXP-2 antibody should be screened for malignancy at the time of presentation.
- 6 October 2023
- Published by Springer Nature in Clinical Rheumatology
- Vol. 42 (12) , 3289-3297
Clinical profile of anti-NXP-2 antibody-positive inflammatory myositis and outcome in an Indian population
Introduction Myositis-specific antibodies (MSA) play an important role in the clinical presentation and prognosis of patients with idiopathic inflammatory myositis (IIM). Anti-NXP-2 is one of the newly described MSA. Objective We aimed to describe various clinical presentations associated with anti-NXP2 antibodies and assess response to treatment. Methods In this retrospective study, the electronic medical records of all patients who tested positive for anti-NXP2 during June 2019 to April 2022 were screened. Details of demography, clinical presentation, and treatment data were recorded. The anti-NXP2 was tested using the Euro line test kit. Any patient who had an intensity of ≥1+ was considered testing positive. The diagnosis of IIM was reviewed after applying the 2017 European League of Rheumatology (EULAR)/American College of Rheumatology (ACR) criteria of myositis. Results Among the 660 suspected patients, 470 (71.2%) patients were positive for IIM, and 28 (5.95%) patients were positive for anti-NXP2. From anti-NXP2-antibody positive, 21/470 (4.46%) patients fulfilled criteria for IIM. Among 12 adult (57.14%) patients with IIM, 7 (58.33%) presented as polymyositis (PM) and 5 (41.6%) as dermatomyositis (DM) with median age at presentation of 45 (IQR: 25–58) years. Calcinosis and subcutaneous oedema were observed in 4 (19%) and 2 (9.52%), respectively; myalgia in 6 (28.6%); and distal muscle weakness in 5 (23.8%) patients. Malignancy at the time of diagnosis was observed in two adults with IIM (16.7%), one with DM (intraductal breast cancer), and another with PM (anaplastic large cell lymphoma). Remaining, 9 had juvenile dermatomyositis (JDM) with a median age of 4 (IQR: 3–8) years. Seven (77.8%) patients with JDM had skin rash specific for DM (heliotrope rash and Gottron’s papule). None of the patients had cardiac and lung involvement, while GI symptoms, especially dysphagia, were present in 5 (23.8%) patients. During a median follow-up of 19 months (IQR: 12–26 months), 19/19 patients reported improvement and were in remission with treatment. Conclusion The current study shows that adult DM patients with anti-NXP-2 autoantibodies have a unique clinical phenotype. Its presentation differs between adult and JDM, even in different parts of the world. Muscle weakness is mild and responds to treatment. Dysphagia needs more time and aggressive IS for improvement as compared to other muscle involvement. Key Points • Anti-NXP-2 antibody presentation varied from adult to child, as in different parts of the world. • In Indian adult patients, non-specific skin manifestations were more common, whereas in JDM, specific skin features were common. • There was less likely involvement of the lung and heart. But more risk of GI involvement requiring aggressive management. • Adult with anti-NXP-2 antibody should be screened for malignancy at the time of presentation.
- 27 January 2021
- Published by Springer Nature in Clinical Rheumatology
- Vol. 40 (7) , 2805-2819
Mycophenolate in idiopathic inflammatory myositis: outcome data of a large South Asian cohort
Background Consensus on treatment of idiopathic inflammatory myositis (IIM), particularly with regard to flares and interstitial lung disease (ILD), does not exist. We studied the long-term outcome and treatment response in our large, retrospective cohort of adult South-Asian patients exclusively with IIM. Methodology Electronic records of IIM patients satisfying inclusion and exclusion criteria were studied longitudinally at presentation, at 3, 6, 12, 18 and 24 months and thereafter yearly till their last follow up (F/u) visit. Depending on clinical, imaging, and muscle enzyme profile during the F/u period, patients were categorised as complete (CR) and partial responders (PRs). Parameters favouring CR were assessed using multivariate logistic regression analysis. Outcome parameters and flares on immunosuppressants (IS) were then assessed in patients with/without ILD. Results Two hundred thirty-two patients with median F/u duration of 44.5 months (25–80.25) were included. ILD was seen in 40.1%. Patients with non-Jo1 anti-synthetase antibodies (n=26) were numerically more than those with Jo-1 antibody (n=24). CR status was attained by 50.9% patients. Absence of pericardial effusion (p=0.042, OR 4.223, 95% CI: 1.05–16.9) and presence of Gottron’s rash (p=0.044, OR 1.78, 95% CI 1.017–3.121) at baseline predicted CR by multivariate regression. Majority received mycophenolate during the entire F/u period. Discontinuation of steroids was feasible in 51.7% after a median duration of 24 months (18–42). After excluding patients with ILD, flares were numerically lesser in patients only on mycophenolate compared with those only on methotrexate (p=0.06). Further flares were curtailed when switched from other agents to mycophenolate. Conclusion Mycophenolate is an effective treatment option in IIM patients with and without co-existing ILD. Presence of Gottron’s rash and absence of pericardial effusion were found to be predictors of favourable clinical outcome in this largest single-centre study. Key points • This largest single-centre study of South Asian adult patients with idiopathic inflammatory myositis showed good clinical outcome and survival with combination treatment regimen consisting of upfront immunosuppressant especially mycophenolate mofetil or sodium (MMF/MMS) along with tapering doses of steroids. • Absence of pericardial involvement and presence of Gottron’s rash were predictors of complete responders in our overall patient cohort. • Testing anti-Jo-1 antibody alone during evaluation of myositis will overlook important prognostic biomarkers such as the presence of non-Jo 1 antisynthetase autoantibodies (PL-7, PL-12, EJ and OJ) as well as Ro52; our cohort had more patients with non-Jo 1 antibodies than Jo-1 antibody; hence, there is a strong case for testing the entire spectrum of myositis autoantibodies in IIM. • Patients on MMF/MMS therapy from onset or even those switched to mycophenolate later had a better outcome, irrespective of their interstitial lung disease status.
- 27 January 2021
- Published by Springer Nature in Clinical Rheumatology
- Vol. 40 (7) , 2805-2819
Mycophenolate in idiopathic inflammatory myositis: outcome data of a large South Asian cohort
Background Consensus on treatment of idiopathic inflammatory myositis (IIM), particularly with regard to flares and interstitial lung disease (ILD), does not exist. We studied the long-term outcome and treatment response in our large, retrospective cohort of adult South-Asian patients exclusively with IIM. Methodology Electronic records of IIM patients satisfying inclusion and exclusion criteria were studied longitudinally at presentation, at 3, 6, 12, 18 and 24 months and thereafter yearly till their last follow up (F/u) visit. Depending on clinical, imaging, and muscle enzyme profile during the F/u period, patients were categorised as complete (CR) and partial responders (PRs). Parameters favouring CR were assessed using multivariate logistic regression analysis. Outcome parameters and flares on immunosuppressants (IS) were then assessed in patients with/without ILD. Results Two hundred thirty-two patients with median F/u duration of 44.5 months (25–80.25) were included. ILD was seen in 40.1%. Patients with non-Jo1 anti-synthetase antibodies (n=26) were numerically more than those with Jo-1 antibody (n=24). CR status was attained by 50.9% patients. Absence of pericardial effusion (p=0.042, OR 4.223, 95% CI: 1.05–16.9) and presence of Gottron’s rash (p=0.044, OR 1.78, 95% CI 1.017–3.121) at baseline predicted CR by multivariate regression. Majority received mycophenolate during the entire F/u period. Discontinuation of steroids was feasible in 51.7% after a median duration of 24 months (18–42). After excluding patients with ILD, flares were numerically lesser in patients only on mycophenolate compared with those only on methotrexate (p=0.06). Further flares were curtailed when switched from other agents to mycophenolate. Conclusion Mycophenolate is an effective treatment option in IIM patients with and without co-existing ILD. Presence of Gottron’s rash and absence of pericardial effusion were found to be predictors of favourable clinical outcome in this largest single-centre study. Key points • This largest single-centre study of South Asian adult patients with idiopathic inflammatory myositis showed good clinical outcome and survival with combination treatment regimen consisting of upfront immunosuppressant especially mycophenolate mofetil or sodium (MMF/MMS) along with tapering doses of steroids. • Absence of pericardial involvement and presence of Gottron’s rash were predictors of complete responders in our overall patient cohort. • Testing anti-Jo-1 antibody alone during evaluation of myositis will overlook important prognostic biomarkers such as the presence of non-Jo 1 antisynthetase autoantibodies (PL-7, PL-12, EJ and OJ) as well as Ro52; our cohort had more patients with non-Jo 1 antibodies than Jo-1 antibody; hence, there is a strong case for testing the entire spectrum of myositis autoantibodies in IIM. • Patients on MMF/MMS therapy from onset or even those switched to mycophenolate later had a better outcome, irrespective of their interstitial lung disease status.
- Open Access
- 1 March 2019
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 58 (Supplement)
084. DISCOVERY AND VALIDATION OF A NOVEL ANGIOGRAPHIC CLASSIFICATION SCHEME IN TAKAYASU’S ARTERITIS
Background: Takayasu’s arteritis (TAK) is characterized by variable patterns of damage throughout the large arteries.
- 1 March 2019
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 58 (Supplement)
Open Access084. DISCOVERY AND VALIDATION OF A NOVEL ANGIOGRAPHIC CLASSIFICATION SCHEME IN TAKAYASU’S ARTERITIS
Background: Takayasu’s arteritis (TAK) is characterized by variable patterns of damage throughout the large arteries.
- 1 December 2017
- Published by Springer Nature in Rheumatology International
- Vol. 38 (4) , 623-630
Study of serial serum myeloid-related protein 8/14 as a sensitive biomarker in Takayasu arteritis: a single centre study
The aim of the study was to explore utility of serial serum myeloid-related protein 8/14 (MRP8/14) as a biomarker of clinical disease activity and angiographic progression in Takayasu arteritis (TA). Serum MRP8/14 levels were assayed by commercial ELISA for 85 TA patients and 24 healthy controls at baseline, and for 56 and 21 TA patients during follow-up visits R1 and R2, respectively. Disease was categorised as active, indeterminate and stable according to Indian Takayasu Arteritis score (ITAS 2010), ITAS-A(CRP) and angiography. Patients were divided into responders and non-responders/relapsers based on treatment response. Non-parametric tests were used for inter-group comparisons at baseline and during follow-up time points. Generalised Estimating Equation was used to study association between changes in serial MRP8/14 levels and disease activity. At baseline, median MRP8/14 levels were higher in patients with TA than healthy controls [7353 (4524 to11283) vs 4896 (3194 to 8474.5) ng/ml, p = 0.011]. Patients with active disease had higher levels [8552 (5463–12488)] than stable disease [5292.5 (3140.5–7310)], p = 0.002, and healthy controls [4896 (3194–8474.5)], p = 0.001. Changes in serial MRP8/14 level were associated with changes in disease activity, independent of steroid dose, p = 0.000. At R1, MRP 8/14 levels were lower than baseline in responders (n = 38) [9146.0 (6296.8–13693.8) vs 6501 (4314.8–8304.5), p = 0.004], but did not change in non-responders/relapsers (n = 14) [6693.5(4210.8–10516.3) vs 7755.0(5342–10741.0), p = 0.42]. Similar trend was observed at R2. MRP8/14 levels increased during follow-up in 66% and 26.3% of angiographic progressors and non-progressors, respectively. MRP8/14 in TA may act as a novel biomarker with prognostic implications.
- 1 December 2017
- Published by Springer Nature in Rheumatology International
- Vol. 38 (4) , 623-630
Study of serial serum myeloid-related protein 8/14 as a sensitive biomarker in Takayasu arteritis: a single centre study
The aim of the study was to explore utility of serial serum myeloid-related protein 8/14 (MRP8/14) as a biomarker of clinical disease activity and angiographic progression in Takayasu arteritis (TA). Serum MRP8/14 levels were assayed by commercial ELISA for 85 TA patients and 24 healthy controls at baseline, and for 56 and 21 TA patients during follow-up visits R1 and R2, respectively. Disease was categorised as active, indeterminate and stable according to Indian Takayasu Arteritis score (ITAS 2010), ITAS-A(CRP) and angiography. Patients were divided into responders and non-responders/relapsers based on treatment response. Non-parametric tests were used for inter-group comparisons at baseline and during follow-up time points. Generalised Estimating Equation was used to study association between changes in serial MRP8/14 levels and disease activity. At baseline, median MRP8/14 levels were higher in patients with TA than healthy controls [7353 (4524 to11283) vs 4896 (3194 to 8474.5) ng/ml, p = 0.011]. Patients with active disease had higher levels [8552 (5463–12488)] than stable disease [5292.5 (3140.5–7310)], p = 0.002, and healthy controls [4896 (3194–8474.5)], p = 0.001. Changes in serial MRP8/14 level were associated with changes in disease activity, independent of steroid dose, p = 0.000. At R1, MRP 8/14 levels were lower than baseline in responders (n = 38) [9146.0 (6296.8–13693.8) vs 6501 (4314.8–8304.5), p = 0.004], but did not change in non-responders/relapsers (n = 14) [6693.5(4210.8–10516.3) vs 7755.0(5342–10741.0), p = 0.42]. Similar trend was observed at R2. MRP8/14 levels increased during follow-up in 66% and 26.3% of angiographic progressors and non-progressors, respectively. MRP8/14 in TA may act as a novel biomarker with prognostic implications.
- 11 October 2017
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 21 (3) , 732-739
C‐reactive protein gene polymorphisms (rs1205) in Asian Indian patients with Takayasu arteritis: Associations and phenotype correlations
Background/Purpose: Normal C‐reactive protein (CRP) in active Takayasu arteritis (TA) is a dilemma. We attempted to validate our pilot study finding of rs1205 in CRP gene being protective against TA.Methods: Genomic DNA of 104 patients and 185 sex‐matched healthy controls were genotyped for rs1205 by Taqman assay. Clinical details, demography, angiographic and activity scores (Indian Takayasu arteritis score 2010) were recorded prospectively at baseline and during follow‐up visits for 12 months. Minor allele frequency (MAF) and genotype distribution between patients and controls as well as patient subgroups were compared using χ2 test with Bonferroni correction (pc) and logistic regression was performed to determine independent associations.Results: The majority of patients (n = 84) and controls (n = 166) were females. MAF of T allele of rs1205 was less frequent in patients (27%) as compared to controls (37.6%), P = 0.013, pc = 0.026 with an odds ratio of 0.632 irrespective of gender. Frequency of CC genotype was higher in cases (53.8%) than controls (37.3%), P = 0.006, pc = 0.018. A dominant model of genotype‐phenotype association revealed CC to be associated with more frequent coronary arterial and ascending aorta involvement than the other genotypes clubbed together (P = 0.01 and P = 0.014, respectively). Blunted CRP response seems to be less frequent in patients with CC genotype (P = 0.064).Conclusion: T allele of rs1205 in CRP gene was less frequent in TA. CC genotype was associated with involvement of coronary arteries and ascending aorta. CC genotype was less commonly associated with blunted CRP response (CT + TT > CC).
- 11 October 2017
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 21 (3) , 732-739
C‐reactive protein gene polymorphisms (rs1205) in Asian Indian patients with Takayasu arteritis: Associations and phenotype correlations
Background/Purpose: Normal C‐reactive protein (CRP) in active Takayasu arteritis (TA) is a dilemma. We attempted to validate our pilot study finding of rs1205 in CRP gene being protective against TA.Methods: Genomic DNA of 104 patients and 185 sex‐matched healthy controls were genotyped for rs1205 by Taqman assay. Clinical details, demography, angiographic and activity scores (Indian Takayasu arteritis score 2010) were recorded prospectively at baseline and during follow‐up visits for 12 months. Minor allele frequency (MAF) and genotype distribution between patients and controls as well as patient subgroups were compared using χ2 test with Bonferroni correction (pc) and logistic regression was performed to determine independent associations.Results: The majority of patients (n = 84) and controls (n = 166) were females. MAF of T allele of rs1205 was less frequent in patients (27%) as compared to controls (37.6%), P = 0.013, pc = 0.026 with an odds ratio of 0.632 irrespective of gender. Frequency of CC genotype was higher in cases (53.8%) than controls (37.3%), P = 0.006, pc = 0.018. A dominant model of genotype‐phenotype association revealed CC to be associated with more frequent coronary arterial and ascending aorta involvement than the other genotypes clubbed together (P = 0.01 and P = 0.014, respectively). Blunted CRP response seems to be less frequent in patients with CC genotype (P = 0.064).Conclusion: T allele of rs1205 in CRP gene was less frequent in TA. CC genotype was associated with involvement of coronary arteries and ascending aorta. CC genotype was less commonly associated with blunted CRP response (CT + TT > CC).
- 23 June 2017
- Published by Springer Nature in Clinical Rheumatology
- Vol. 36 (10) , 2243-2251
TNFα blockers followed by continuation of sulfasalazine and methotrexate combination: a retrospective study on cost saving options of treatment in Spondyloarthritis
High cost deters continuous use of tumor necrosis factor α blockers (TNFi) in developing countries. The objective of this study was to evaluate outcome and expenditure incurred in Spondyloarthritis (SpA) patients beyond a year of follow-up after receiving four doses of infliximab (IFX) over and above background therapy of methotrexate (MTX) and sulfasalazine (SSZ) combination. Electronic medical records were screened for patients with SpA satisfying the Assessment of Spondyloarthritis International Society (ASAS) criteria between 2008 and 2014. Patients who completed at least 1 year of follow-up after receiving four doses of IFX (5 mg/kg at 0, 2, 6, and 14 weeks) on a background therapy of MTX (10–25 mg/week) and SSZ (2–3 g/day) combination were enrolled after obtaining an informed consent. Primary outcome assessed was “time to disease flare”. Changes in acute phase reactants, patient reported outcomes (BASDAI, BASFI), and cost were also assessed. Forty-five patients were enrolled. Mean (SD) duration of follow up after fourth IFX dose was 28.9 (18.7) months. Disease flare occurred in 33.3% (15/45) after a mean (SD) duration of 14.5 (10.8) months as compared to 4–6 months described in literature on discontinuing TNFi. Reduction in ESR, CRP, BASDAI and BASFI continued to be statistically significant at follow-up as compared to baseline. As compared to continuous IFX therapy, this treatment reduced cost by 57.1% for each patient-month of follow-up. Short course IFX dosing followed by continuation of MTX and SSZ combination can prolong time to disease flare and decrease requirement for additional IFX dose in SpA. This regimen could be a cost saving option for patients with SpA.
- 23 June 2017
- Published by Springer Nature in Clinical Rheumatology
- Vol. 36 (10) , 2243-2251
TNFα blockers followed by continuation of sulfasalazine and methotrexate combination: a retrospective study on cost saving options of treatment in Spondyloarthritis
High cost deters continuous use of tumor necrosis factor α blockers (TNFi) in developing countries. The objective of this study was to evaluate outcome and expenditure incurred in Spondyloarthritis (SpA) patients beyond a year of follow-up after receiving four doses of infliximab (IFX) over and above background therapy of methotrexate (MTX) and sulfasalazine (SSZ) combination. Electronic medical records were screened for patients with SpA satisfying the Assessment of Spondyloarthritis International Society (ASAS) criteria between 2008 and 2014. Patients who completed at least 1 year of follow-up after receiving four doses of IFX (5 mg/kg at 0, 2, 6, and 14 weeks) on a background therapy of MTX (10–25 mg/week) and SSZ (2–3 g/day) combination were enrolled after obtaining an informed consent. Primary outcome assessed was “time to disease flare”. Changes in acute phase reactants, patient reported outcomes (BASDAI, BASFI), and cost were also assessed. Forty-five patients were enrolled. Mean (SD) duration of follow up after fourth IFX dose was 28.9 (18.7) months. Disease flare occurred in 33.3% (15/45) after a mean (SD) duration of 14.5 (10.8) months as compared to 4–6 months described in literature on discontinuing TNFi. Reduction in ESR, CRP, BASDAI and BASFI continued to be statistically significant at follow-up as compared to baseline. As compared to continuous IFX therapy, this treatment reduced cost by 57.1% for each patient-month of follow-up. Short course IFX dosing followed by continuation of MTX and SSZ combination can prolong time to disease flare and decrease requirement for additional IFX dose in SpA. This regimen could be a cost saving option for patients with SpA.
- Open Access
- 1 June 2017
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 76 (Suppl 2) , 316
THU0298 Long term outcome of patients with takayasu arteritis- a single centre study
Background Takayasu Arteritis (TA), a large vessel vasculitis is characterised by a variable clinical course and outcome that differs across populations. Most studies are limited by small sample size. Objectives (i) To study treatment outcome in our TA patients with a follow up of ≥12 months (ii) Construct a prediction model for subset of patients with sustained inactive disease. Methods Consecutive patients with TA attending our clinics between 1998 and April 2016 were recruited. Details of baseline demography, clinical profile, angiography, disease extent using DEI.Tak, laboratory parameters and TADS (Takayasu arteritis damage score) were recorded. At each follow up visit, disease activity was assessed by Indian Takayasu Activity score (ITAS-2010 (CRP) and imaging, while damage was assessed by TADS for patients who followed up for ≥12 months (retrospectively for 179 and prospectively for 72 patients). Treatment response was classified as complete response (CR), partial response and no-response. Sustained inactive disease was defined as maintenance of CR throughout the follow up with steroid dose reduced to ≤5mg/day. Relapse was defined as return of active disease after CR. Statistical analysis was performed using SPSS-16. Intergroup comparisons were performed by nonparametric test. Logistic regression was used for determining independent associations. Optimal cut off values were determined using receiver operating curve and prediction model was constructed. Efficacy of medications was compared by Cox proportional hazards model. Results Baseline details were noted for 503 patients: mean age at onset of 25.6±11.1 years, disease duration 12 (6–48) months, diagnostic delay 6 (3–24) months) and 77.9% were females. Among 251 patients with follow up of at least 12 months, 95.2% received steroids along with II line immunosuppressant in 93.6% (mycophenolate in 63.7%). Tocilizumab was given induction or rescue therapy to 44 patients. Revascularisation procedures were performed in 71.7%. Complete (ITAS 2010 = 0, CRP Conclusions Medical management arrested disease activity, damage progression and mortality in our cohort. Low baseline CRP and DEI.Tak scores and type 4 disease independently predicted sustained inactive disease. Disclosure of Interest None declared
- 1 June 2017
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 76 (Suppl 2) , 316
Open AccessTHU0298 Long term outcome of patients with takayasu arteritis- a single centre study
Background Takayasu Arteritis (TA), a large vessel vasculitis is characterised by a variable clinical course and outcome that differs across populations. Most studies are limited by small sample size. Objectives (i) To study treatment outcome in our TA patients with a follow up of ≥12 months (ii) Construct a prediction model for subset of patients with sustained inactive disease. Methods Consecutive patients with TA attending our clinics between 1998 and April 2016 were recruited. Details of baseline demography, clinical profile, angiography, disease extent using DEI.Tak, laboratory parameters and TADS (Takayasu arteritis damage score) were recorded. At each follow up visit, disease activity was assessed by Indian Takayasu Activity score (ITAS-2010 (CRP) and imaging, while damage was assessed by TADS for patients who followed up for ≥12 months (retrospectively for 179 and prospectively for 72 patients). Treatment response was classified as complete response (CR), partial response and no-response. Sustained inactive disease was defined as maintenance of CR throughout the follow up with steroid dose reduced to ≤5mg/day. Relapse was defined as return of active disease after CR. Statistical analysis was performed using SPSS-16. Intergroup comparisons were performed by nonparametric test. Logistic regression was used for determining independent associations. Optimal cut off values were determined using receiver operating curve and prediction model was constructed. Efficacy of medications was compared by Cox proportional hazards model. Results Baseline details were noted for 503 patients: mean age at onset of 25.6±11.1 years, disease duration 12 (6–48) months, diagnostic delay 6 (3–24) months) and 77.9% were females. Among 251 patients with follow up of at least 12 months, 95.2% received steroids along with II line immunosuppressant in 93.6% (mycophenolate in 63.7%). Tocilizumab was given induction or rescue therapy to 44 patients. Revascularisation procedures were performed in 71.7%. Complete (ITAS 2010 = 0, CRP Conclusions Medical management arrested disease activity, damage progression and mortality in our cohort. Low baseline CRP and DEI.Tak scores and type 4 disease independently predicted sustained inactive disease. Disclosure of Interest None declared